HOME >> BIOLOGY >> NEWS
Monsanto to share technologies with Danforth Center to support global cassava research

ted Nations Human Development Report 2001 also encouraged greater public investment in research and development to ensure that biotechnology is used to meet the agricultural needs of the world's poor.

"By sharing our technology and other scientific knowledge, Monsanto hopes to encourage other companies and technology developers to do the same, said Robb Fraley, Chief Technology Officer of Monsanto.

Working together in public and private sector partnerships promotes a wide variety of discoveries to enhance food security and nutrition throughout the developing world. We look forward to continuing our support of the cassava research program as it develops, said Fraley.

Monsanto also is supporting the Danforth Centers efforts to develop virus-resistant cassava through a multi-year grant from the companys philanthropic organization, the Monsanto Fund. Monsantos contributions to the Danforth Center are in keeping with the New Monsanto Pledge and its commitment to sharing knowledge and technology with public institutions to benefit people and the environment, particularly in the developing world.

In August 2000, Monsanto granted similar royalty-free licenses to the inventors of golden rice, which is being developed to combat vitamin A deficiency in developing countries. Other sharing projects include providing access to a working draft of the rice genome and participating in work to develop virus-resistant sweet potatoes in Africa and papayas in South East Asia.


'"/>

Contact: Shannon Troughton
314-694-2320
Monsanto Company
16-Apr-2002


Page: 1 2

Related biology news :

1. Washington University in St. Louis, Monsanto Co., awarded crop protection patent
2. Monsanto and researchers celebrate first anniversary of sharing rice genome sequence data
3. Monsanto adds support for golden rice; opens its rice genome sequence data to worldwide research community
4. Monsantos modified soya beans dont agree with the heat
5. Bone, enamel, dentine, milk & saliva share gene family
6. K-State researchers share $1 million grant to study insect pests
7. Cross-species comparison reveals shared features between tumorigenesis and organogenesis
8. Scientists discover that metastases share a similar genetic profile to their primary tumour
9. Drug addiction, learning share common brain protein
10. Monkey talk, human speech share left-brain processing
11. Lions share of the best of Asias progressive minds in science and medicine convene

Post Your Comments:
(Date:6/8/2015)... SAN DIEGO , June 8, 2015  Trovagene, Inc. ... announced today that clinical data featuring its Precision Cancer Monitoring ... Cancer Markers and Liquid Biopsies conference in San ... the AACR Precision Medicine Series: Integrating Clinical Genomics and ... on June 13-16. "We continue ...
(Date:6/5/2015)... GERMANTOWN, Md. , June 5, 2015  Intrexon ... synthetic biology, today announced that it has determined the ... of all of its 17,830,305 shares of ZIOPHARM Oncology, ... or about June 12, 2015, the distribution date, as ... stock, and on warrants to purchase shares of Intrexon ...
(Date:6/1/2015)... -- According to a new market research ... (Touch-based & Touchless), Application (Consumer Electronics, Automotive, & Others), ... Global Forecast to 2020", published by MarketsandMarkets, the Gesture ... $23.55 Billion by 2020, at a CAGR of 28.23% ... market data T ables and   86   ...
Breaking Biology News(10 mins):Clinical Data Featuring Trovagene's Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences 2Clinical Data Featuring Trovagene's Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences 3Clinical Data Featuring Trovagene's Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences 4Intrexon Announces Distribution Ratio for Distribution of ZIOPHARM Shares 2Intrexon Announces Distribution Ratio for Distribution of ZIOPHARM Shares 3Intrexon Announces Distribution Ratio for Distribution of ZIOPHARM Shares 4Gesture Recognition & Touchless Sensing Market Worth $23.55 Billion by 2020 2Gesture Recognition & Touchless Sensing Market Worth $23.55 Billion by 2020 3Gesture Recognition & Touchless Sensing Market Worth $23.55 Billion by 2020 4
(Date:6/26/2015)... MUMBAI, India , June 26, 2015 ... a leading global IT services, consulting and business solutions ... Leader in Worldwide Life Sciences R&D Risk-Based Monitoring by ... MarketScape: Worldwide Life Science R&D Risk-Based Monitoring 2015 Vendor ... The report evaluated eight leading IT services vendors with ...
(Date:6/26/2015)... ... June 26, 2015 , ... ReliantHeart, Inc. , an innovative supplier of ... implant of the HeartAssist5® LVAD (HA5) to the 68th consecutive implant, there has been ... originates in an LVAD is referred to as de novo thrombus. De novo thrombus ...
(Date:6/25/2015)... ... 2015 , ... Students entering the new Hemenway Hall addition ... exclusively using filtered fume hoods that feature Erlab’s GreenFumeHood Filtration Technology . ... needed for their Organic, Inorganic, Analytical, and Physical Chemistry teaching laboratories. Each filtered ...
(Date:6/25/2015)... , June 25, 2015 /PRNewswire/ - Portage Biotech ... , OTC Markets : PTGEF,), is pleased to announce ... US$5,155,080 through issuance of approximately 36.8 million common shares ... two tranches, first tranche closed on June 15, 2015 ... and second and final tranche closed on June 24, ...
Breaking Biology Technology:TCS Recognized as a Leader in Life Sciences R&D Risk-Based Monitoring by IDC MarketScape 2TCS Recognized as a Leader in Life Sciences R&D Risk-Based Monitoring by IDC MarketScape 3TCS Recognized as a Leader in Life Sciences R&D Risk-Based Monitoring by IDC MarketScape 4HeartAssist5® Remote Monitoring has alerted no patterns of de novo thrombus in 68 consecutive implants 2HeartAssist5® Remote Monitoring has alerted no patterns of de novo thrombus in 68 consecutive implants 3This Summer Erlab Completes the Largest Installation of Filtered Fume Hoods in the World 2Portage Completes Non-brokered Private Placement in Two Tranches for a Total Proceeds of US$ 5,155,080 2Portage Completes Non-brokered Private Placement in Two Tranches for a Total Proceeds of US$ 5,155,080 3
Cached News: